Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications
- 1 May 1999
- journal article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 42 (5) , 601-605
- https://doi.org/10.1007/bf02234133
Abstract
Genetic markers have been used to define subgroups of patients within the broad categories of Crohn's disease and ulcerative colitis that may differ in clinical course and response to medical therapy. The tumor necrosis factor microsatellite haplotype a2b1c2d4e1 has been found previously to be present in 24 percent of patients with Crohn's disease and only 5 percent of patients with ulcerative colitis. This study examined associations between this microsatellite haplotype and the postoperative clinical course of patients with ulcerative colitis undergoing ileal pouch-anal anastomosis. As part of a large, controlled, prospective study to correlate genetic markers with clinical phenotypes, tumor necrosis factor microsatellite alleles at five loci (a, b, c, d, and e) were determined from genomic DNA by polymerase chain reaction in 32 patients with a clinical and histopathologic diagnosis of ulcerative colitis who underwent ileal pouch-anal anastomosis for medically unresponsive disease. All patients with ileal pouch-anal anastomosis were also studied prospectively for pouch-specific complications. The tumor necrosis factor haplotype a2b1c2d4e1 was present in 11 patients. Median follow-up was 19 months. Thirteen patients had a pouch-specific complication (12 pouchitis and 1 pouch-perineal fistula). Six of 11 patients (55 percent) with the haplotype had a pouch-specific complication compared with 7 of the 21 patients (33 percent) who did not possess this haplotype (P =0.22). Median time from surgery to pouch-specific complication was eight months. Patients with the haplotype had a median time to pouch-specific complication of three months, whereas patients without the haplotype had a median time of 11 months (P =0.04). In addition, 36 percent of patients with the haplotype had chronic pouch complications vs. only 10 percent of patients without the haplotype (P =0.05). The Crohn's disease-associated tumor necrosis factor haplotype a2b1c2d4e1 may define a subgroup of medically unresponsive patients with ulcerative colitis who are predisposed to a higher incidence of pouch-specific complications after ileal pouch-anal anastomosis.Keywords
This publication has 13 references indexed in Scilit:
- Tumor necrosis factor microsatellites define a Crohn's disease- associated haplotype on chromosome 6Gastroenterology, 1996
- Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.Gut, 1996
- Cytokine production in pouchitis is similar to that in ulcerative colitisDiseases of the Colon & Rectum, 1995
- IIeal Pouch-Anal Anastomoses Complications and Function in 1005 PatientsAnnals of Surgery, 1995
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers.Journal of Clinical Investigation, 1993
- Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews.Gut, 1993
- Tumor Necrosis Factor and IL-1β Expression in Pediatric Patients with Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1993
- Distinct associations of HLA Class II genes with inflammatory bowel diseaseGastroenterology, 1993
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990